These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 21055663)

  • 21. Improvement of fog and exercise-induced bronchoconstriction after local and subcutaneous immunotherapy in mite asthma.
    Corbetta L; Pesiri P; Ferro G; Mander A
    Allergol Immunopathol (Madr); 1992; 20(2):61-6. PubMed ID: 1442451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics.
    Blumberga G; Groes L; Haugaard L; Dahl R
    Allergy; 2006 Jul; 61(7):843-8. PubMed ID: 16792582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The safety of sublingual immunotherapy with one or more allergens in adults.
    Lombardi C; Gargioni S; Cottini M; Canonica GW; Passalacqua G
    Allergy; 2008 Mar; 63(3):375-6. PubMed ID: 18269680
    [No Abstract]   [Full Text] [Related]  

  • 24. Local immunotherapy for chronic respiratory allergic pathology with allergen aerosols. II. Treatment of bronchial asthma.
    Moshkevich VS
    Allergol Immunopathol (Madr); 1985; 13(4):317-21. PubMed ID: 4083229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of specific immunotherapy to mosquito bites.
    Ariano R; Panzani RC
    Eur Ann Allergy Clin Immunol; 2004 Apr; 36(4):131-8. PubMed ID: 15180354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flexible approaches in the design of subcutaneous immunotherapy protocols for Hymenoptera venom allergy.
    Alessandrini AE; Berra D; Rizzini FL; Mauro M; Melchiorre A; Rossi F; Spezia D; Stanizzi R; Ricciardi L; Burastero SE
    Ann Allergy Asthma Immunol; 2006 Jul; 97(1):92-7. PubMed ID: 16892788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of immunotherapy with therapeutic vaccines containing depigmented and polymerized allergen extracts.
    Casanovas M; Martín R; Jiménez C; Caballero R; Fernández-Caldas E
    Clin Exp Allergy; 2007 Mar; 37(3):434-40. PubMed ID: 17359393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local reactions during allergen immunotherapy do not require dose adjustment.
    Tankersley MS; Butler KK; Butler WK; Goetz DW
    J Allergy Clin Immunol; 2000 Nov; 106(5):840-3. PubMed ID: 11080704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allergen immunotherapy-induced biphasic systemic reactions: incidence, characteristics, and outcome: a prospective study.
    Confino-Cohen R; Goldberg A
    Ann Allergy Asthma Immunol; 2010 Jan; 104(1):73-8. PubMed ID: 20143649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic reactions to inhalant immunotherapy using 1:1 target dosing.
    Holland CL; Samuels KM; Baldwin JL; Greenhawt MJ
    Ann Allergy Asthma Immunol; 2014 May; 112(5):453-8. PubMed ID: 24631183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Allergy vaccination with only 4 injections per year].
    Krankenpfl J; 2005; 43(7-10):261-2. PubMed ID: 16515332
    [No Abstract]   [Full Text] [Related]  

  • 32. Non-fatal systemic reactions to subcutaneous immunotherapy: a 20-year experience comparison of two 10-year periods.
    Ragusa VF; Massolo A
    Eur Ann Allergy Clin Immunol; 2004 Feb; 36(2):52-5. PubMed ID: 15061395
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Value of accelerated hyposensitization with mixed allergens in severe childhood asthma].
    Just J; Bodart E; Pothel E; Boulé M; Grimfeld A; Tournier G
    Ann Pediatr (Paris); 1992 Apr; 39(4):236-40. PubMed ID: 1616237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of sublingual grass pollen immunotherapy after anaphylaxis.
    Nichani JR; de Carpentier J
    J Laryngol Otol; 2009 Jun; 123(6):683-4. PubMed ID: 18501039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sublingual immunotherapy is not always a safe alternative to subcutaneous immunotherapy.
    Cochard MM; Eigenmann PA
    J Allergy Clin Immunol; 2009 Aug; 124(2):378-9. PubMed ID: 19541352
    [No Abstract]   [Full Text] [Related]  

  • 36. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Analysis of the efficacy of specific immunotherapy with house-dust mite extracts in adults with allergic rhinitis and/or asthma].
    Polzehl D; Keck T; Riechelmann H
    Laryngorhinootologie; 2003 Apr; 82(4):272-80. PubMed ID: 12717603
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient perceptions regarding local reactions from allergen immunotherapy injections.
    Coop CA; Tankersley MS
    Ann Allergy Asthma Immunol; 2008 Jul; 101(1):96-100. PubMed ID: 18681091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Preventive immunotherapy].
    Boquete M; Carballada F; Expósito F; González A
    Allergol Immunopathol (Madr); 2000; 28(3):89-93. PubMed ID: 10867376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of subcutaneous versus mucosal (intranasal) allergen-specific rush immunotherapy in experimental feline asthma.
    Lee-Fowler TM; Cohn LA; DeClue AE; Spinka CM; Reinero CR
    Vet Immunol Immunopathol; 2009 May; 129(1-2):49-56. PubMed ID: 19144412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.